Cargando…

Science Review: Vasopressin and the cardiovascular system part 2 – clinical physiology

Vasopressin is emerging as a rational therapy for vasodilatory shock states. In part 1 of the review we discussed the structure and function of the various vasopressin receptors. In part 2 we discuss vascular smooth muscle contraction pathways with an emphasis on the effects of vasopressin on ATP-se...

Descripción completa

Detalles Bibliográficos
Autores principales: Holmes, Cheryl L, Landry, Donald W, Granton, John T
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC420051/
https://www.ncbi.nlm.nih.gov/pubmed/14975041
http://dx.doi.org/10.1186/cc2338
_version_ 1782121460046757888
author Holmes, Cheryl L
Landry, Donald W
Granton, John T
author_facet Holmes, Cheryl L
Landry, Donald W
Granton, John T
author_sort Holmes, Cheryl L
collection PubMed
description Vasopressin is emerging as a rational therapy for vasodilatory shock states. In part 1 of the review we discussed the structure and function of the various vasopressin receptors. In part 2 we discuss vascular smooth muscle contraction pathways with an emphasis on the effects of vasopressin on ATP-sensitive K(+ )channels, nitric oxide pathways, and interaction with adrenergic agents. We explore the complex and contradictory studies of vasopressin on cardiac inotropy and coronary vascular tone. Finally, we summarize the clinical studies of vasopressin in shock states, which to date have been relatively small and have focused on physiologic outcomes. Because of potential adverse effects of vasopressin, clinical use of vasopressin in vasodilatory shock should await a randomized controlled trial of the effect of vasopressin's effect on outcomes such as organ failure and mortality.
format Text
id pubmed-420051
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-4200512004-06-04 Science Review: Vasopressin and the cardiovascular system part 2 – clinical physiology Holmes, Cheryl L Landry, Donald W Granton, John T Crit Care Review Vasopressin is emerging as a rational therapy for vasodilatory shock states. In part 1 of the review we discussed the structure and function of the various vasopressin receptors. In part 2 we discuss vascular smooth muscle contraction pathways with an emphasis on the effects of vasopressin on ATP-sensitive K(+ )channels, nitric oxide pathways, and interaction with adrenergic agents. We explore the complex and contradictory studies of vasopressin on cardiac inotropy and coronary vascular tone. Finally, we summarize the clinical studies of vasopressin in shock states, which to date have been relatively small and have focused on physiologic outcomes. Because of potential adverse effects of vasopressin, clinical use of vasopressin in vasodilatory shock should await a randomized controlled trial of the effect of vasopressin's effect on outcomes such as organ failure and mortality. BioMed Central 2004 2003-06-26 /pmc/articles/PMC420051/ /pubmed/14975041 http://dx.doi.org/10.1186/cc2338 Text en Copyright © 2004 BioMed Central Ltd
spellingShingle Review
Holmes, Cheryl L
Landry, Donald W
Granton, John T
Science Review: Vasopressin and the cardiovascular system part 2 – clinical physiology
title Science Review: Vasopressin and the cardiovascular system part 2 – clinical physiology
title_full Science Review: Vasopressin and the cardiovascular system part 2 – clinical physiology
title_fullStr Science Review: Vasopressin and the cardiovascular system part 2 – clinical physiology
title_full_unstemmed Science Review: Vasopressin and the cardiovascular system part 2 – clinical physiology
title_short Science Review: Vasopressin and the cardiovascular system part 2 – clinical physiology
title_sort science review: vasopressin and the cardiovascular system part 2 – clinical physiology
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC420051/
https://www.ncbi.nlm.nih.gov/pubmed/14975041
http://dx.doi.org/10.1186/cc2338
work_keys_str_mv AT holmescheryll sciencereviewvasopressinandthecardiovascularsystempart2clinicalphysiology
AT landrydonaldw sciencereviewvasopressinandthecardiovascularsystempart2clinicalphysiology
AT grantonjohnt sciencereviewvasopressinandthecardiovascularsystempart2clinicalphysiology